DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Allergy Innovation | Explore DBV Technologies' groundbreaking Viaskin Peanut patch, offering a non-invasive solution for peanut allergies in children with promising clinical results |
Market Potential | Delve into the projected $2 billion annual peak sales for Viaskin Peanut, driven by strong physician intent and a growing patient base |
Financial Outlook | Learn about DBV's improved financial position, with $128 million in cash and potential for $180 million more, despite current cash burn concerns |
Analyst Perspectives | Discover varied analyst price targets ranging from $10 to $21, reflecting optimism about DBV's future prospects in the allergy treatment market |
Metrics to compare | DBVT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDBVTPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.1x | −2.3x | −0.6x | |
PEG Ratio | 0.14 | −0.05 | 0.00 | |
Price/Book | 4.5x | 2.3x | 2.6x | |
Price / LTM Sales | 101.4x | 7.7x | 3.4x | |
Upside (Analyst Target) | 38.1% | 114.7% | 35.5% | |
Fair Value Upside | Unlock | 9.5% | 3.7% | Unlock |